Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/40475
DC FieldValueLanguage
dc.contributor.authorYang, M.D.en_US
dc.contributor.author邱繡河zh_TW
dc.contributor.authorWu, C.C.en_US
dc.contributor.authorChiou, S.H.en_US
dc.contributor.authorChiu, C.F.en_US
dc.contributor.authorLin, T.Y.en_US
dc.contributor.authorChiang, I.P.en_US
dc.contributor.authorChow, K.C.en_US
dc.contributor.author周寬基zh_TW
dc.date2003zh_TW
dc.date.accessioned2014-06-06T08:03:50Z-
dc.date.available2014-06-06T08:03:50Z-
dc.identifier.issn1021-335Xzh_TW
dc.identifier.urihttp://hdl.handle.net/11455/40475-
dc.description.abstractDihydrodiol dehydrogenase (DDH) is one of the major enzymes catabolizing polycyclic aromatic hydrocarbons in the liver. Although four DDH isoforms have been detected in the normal liver, only DDH1 and DDH2 have been detected in cancer cells of lung and esophagus. Moreover, the available information about hepatic pathophysiological regulation of DDH expression is limited. Therefore we addressed the question of DDH expression in patients with liver disorders, in particular, patients with hepatocellular carcinoma (HCC). Expression of DDH1/2 was determined by immunohistochemistry, immunoblotting and reverse transcription-polymerase chain reaction (RT-PCR) in 52 patients with resected HCC. DDH1/2 expression was detected in 31 (59.6%) of 52 pathological sections. Frequency of DDH1/2 expression was significantly higher in patients with tumor size >2 cm, and in those who had early local recurrence. In addition to the tumor size and frequency of local recurrence, our results further indicated that expression of DDH1/2 was correlated with those of cyclooxygenase 2 (COX-2), interleukin-6 (IL-6), microsomal epoxide hydrolase (mEpH) and Soluble epoxide hydrolase (sEpH) in HCC patients. Interestingly, the expression of DDH1/2 was found inversely correlated with that of glutathione S-transferase (GST) and NADPH p450 reductase (NPR). In conclusion, these results indicate that DDH expression was significantly decreased in about 40% of HCC patients. However, in the bordering nonneoplastic region of liver DDH1/2 expression increased, and the increased DDH1/2 expression correlated with tumor size and the disease progression.en_US
dc.language.isoen_USzh_TW
dc.relationOncology Reportsen_US
dc.relation.ispartofseriesOncology Reports, Volume 10, Issue 2, Page(s) 271-276.en_US
dc.subjectdihydrodiol dehydrogenaseen_US
dc.subjectcyclooxygenase 2en_US
dc.subjectglutathione S-transferaseen_US
dc.subjectepoxide hydrolaseen_US
dc.subjectrecurrenceen_US
dc.subjectcarcinogenesisen_US
dc.subjecthepatitis-b carriersen_US
dc.subjects-transferase m1en_US
dc.subjectgenetic polymorphismsen_US
dc.subjectcanceren_US
dc.subjectcellsen_US
dc.subjectaflatoxinen_US
dc.subjectt1en_US
dc.subjectoverexpressionen_US
dc.subjectactivationen_US
dc.subjectinductionen_US
dc.titleReduction of dihydrodiol dehydrogenase expression in resected hepatocellular carcinomaen_US
dc.typeJournal Articlezh_TW
Appears in Collections:生物醫學研究所
文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.